Lisdexamfetamine Dimesylate Capsule
Product Images NDC 72162-2451

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Lisdexamfetamine Dimesylate (NDC 72162-2451). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label (Lbl721622451)

This text provides information from a package insert of Lisdexamfetamine 10 mg capsules. It includes details such as the NDC code, dosage, storage instructions, and manufacturer information. Patients are advised to keep this medication out of reach of children.*

FDA Label Image

Chemical Structure (Lisdexcaps 01)

FDA Label Image

Figure 1 (Lisdexcaps 02)

This text addresses special populations, focusing on gender (male/female) and age groups ranging from 65 to over 80 years. It also mentions renal impairment levels such as mild, moderate, severe, and end-stage renal disease. The information seems to include statistics or measurements related to fold change and a 90% confidence interval. Additionally, there is reference to changes relative to a baseline.*

FDA Label Image

Figure 2 (Lisdexcaps 03)

FDA Label Image

Figure 3 (Lisdexcaps 04)

This is a list of various drugs such as Guanfacine, Venlafaxine, Dextromethorphan, and Omeprazole, along with their interactions as substrates for different cytochrome P450 enzymes. Additionally, it includes pharmacokinetic parameters such as Cmax and AUC, as well as discussing fold change relative to a reference. The text seems to be related to drug interactions and pharmacokinetic studies.*

FDA Label Image

Figure 4 (Lisdexcaps 05)

This text appears to be displaying the LS Mean (SE) SKAMP Deportment Scores for two different conditions: Placebo and Lisdexamfetamine, across various time points post-dose. The data appears to be organized in a table format, with information for hours 0, 2, and 5 post-dose. It seems to be part of a study or analysis involving the effects of the two mentioned conditions on SKAMP Deportment Scores.*

FDA Label Image

Figure 5 (Lisdexcaps 06)

FDA Label Image

Figure 6 (Lisdexcaps 07)

This text appears to display LS Mean (SE) PERMP Total Scores for lisdexamfetamine at various time points post-dose. The scores for each time point seem to range from 250 to 330. Additionally, there is a mention of a "Phacebo" group. Time post-dose is also indicated, with data at 4, 8, 12, and 14 hours after dosing.*

FDA Label Image

Figure 7 (Lisdexcaps 08)

FDA Label Image

Figure 8 (Lisdexcaps 09)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.